Literature DB >> 2702041

Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines.

R D Whelan1, L K Hosking, A J Townsend, K H Cowan, B T Hill.   

Abstract

Modified glutathione S-transferase (GST) activity was detected in MCF-7 cell lines selected in vitro for modest levels of resistance (2.6- to 13.7-fold) not only to Adriamycin but also to Novantrone, vincristine (VCR), and etoposide (VP-16). Western blot analysis revealed a qualitative increase in the expression of the pi class GST isozyme and some apparent down regulation of the mu class in these resistant lines relative to the parental line. Overexpression of GST pi protein was also observed after in vitro exposure of MCF-7 cells to fractionated x-irradiation, which resulted in a subline that exhibited 5-fold resistance to VCR and 3-fold resistance to VP-16. Northern blot analysis provided qualitative evidence that these changes in GST pi and mu appeared to be at the transcriptional level in these VCR- and VP-16-resistant MCF-7 sublines. In contrast, similarly selected VCR-resistant, VP-16-resistant, and x-ray-pretreated-resistant sublines, derived from the SuSa cell line established from a human testicular teratoma, did not exhibit significant alterations in GST isozyme profiles compared with their parental cell lines. All parental and resistant SuSa lines that were studied expressed the GST pi isozyme constitutively. Total glutathione content and glutathione peroxidase activities were not modified in parallel with the GST alterations in these human tumor drug resistant sublines. These data suggest that the increased cellular GST activity was associated with selection of resistance to many of the drugs associated with the multidrug resistant phenotype in MCF-7 sublines but that this was not the case for the other human tumor cell line (SuSa) tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702041     DOI: 10.3727/095535489820875057

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  9 in total

1.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.

Authors:  Degang Shi; Genming Shi; Gang Huang; Jiren Zhang; Eric Lartigau
Journal:  J Exp Clin Cancer Res       Date:  2009-06-02

Review 3.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue.

Authors:  P Terrier; A J Townsend; J M Coindre; T J Triche; K H Cowan
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

5.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

Authors:  G MacGrogan; L Mauriac; M Durand; F Bonichon; M Trojani; I de Mascarel; J M Coindre
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

6.  Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?

Authors:  B G Campling; K Baer; H M Baker; Y M Lam; S P Cole
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

7.  Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

Authors:  A Losada; J M López-Oliva; J M Sánchez-Puelles; L F García-Fernández
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

Review 8.  Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.

Authors:  Manfred Volm; Thomas Efferth
Journal:  Front Oncol       Date:  2015-12-17       Impact factor: 6.244

9.  Protein expression profiles indicative for drug resistance of non-small cell lung cancer.

Authors:  M Volm; R Koomägi; J Mattern; T Efferth
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.